Acquisition triggers a 90-day window where the new therapeutic surface either consolidates Neurocrine's authority or splits it. The strategy is on this page. Read in 5 minutes · forward to corp-comms or digital · the $250 audit formalizes scope before any compliance-sensitive content ships. No Calendly · no funnel · no email gate.
Operator-honest read on what changes for Neurocrine's search surface the day an acquisition closes. The good, the flag, and what it means for compounding.
Neurocrine is a top-50 biopharma with FDA-approved therapies in tardive dyskinesia (Ingrezza), endometriosis (Orilissa partner), and a deep neuroscience + endocrinology pipeline. Domain authority is real. Existing canonical surface is publisher-class. New acquired indications inherit that authority IF they are routed correctly.
The default failure mode post-acquisition: the acquired company's site stays up, slowly fades, and bleeds search authority for 18+ months while corp-dev figures out content migration. By the time the migration happens, Google has decided the acquired surface is decayed. Authority does not transfer cleanly. Fixable, but only inside the 90-day window.
21 CFR Part 11 electronic records, FDA Title 21 advertising guardrails, HIPAA for patient-facing pages, SOC 2 for vendor due diligence on any CRO/CMO partners. This is not Heirloom-style consumer SEO · this is biotech publishing where compliance is the substrate, not the afterthought.
HCPs (clinical specialists searching mechanism + dosing + trial data) · payers (J-code, formulary, prior-auth language) · patients + caregivers (pre-Rx education, side-effect honesty) · investors (post-acquisition pipeline narrative). Four distinct search intents · one canonical surface · careful schema work to keep them addressable without overlap.
Ranked by post-acquisition compounding strength · informed by six months of compliance-vertical substrate building in SOC 2 / HIPAA / FDA-adjacent space. These are real buyer queries, not generic biotech content marketing.
Clinical specialists searching mechanism of action, dosing protocols, switching guidance, contraindications. Lower volume per query but very high commercial intent · these queries precede script-writing.
[acquired-drug-name] mechanism of action for movement disorders[acquired-drug-name] dosing protocol for adult patientsswitching from [comparator] to [acquired-drug-name][indication] treatment algorithm 2026 updateVMAT2 inhibitor comparison clinical guidancePatients and caregivers searching before the doctor visit. FDA-aligned, operator-honest, written within label boundaries. These pages drive HCP-visit conversion not script conversion · different KPI, equally important.
what to ask my doctor about [indication] treatmentside effects of [drug class] honest patient guidehow long does [drug name] take to worktardive dyskinesia treatment questions for neurologistendometriosis treatment options 2026 patient guidePharmacy directors, payer reviewers, and prior-auth specialists searching for coverage criteria, J-codes, step-therapy positioning. Bottom-funnel · decision-stage · highest reimbursement impact when ranked.
[drug name] prior authorization criteria 2026[drug name] J-code billing guide[drug name] step therapy formulary positioning[indication] medical policy criteria payer review[drug name] specialty pharmacy distributionOperator-honest compliance substrate that signals to Google + AI Overviews that Neurocrine is the canonical authority for FDA-regulated digital publishing. Builds E-E-A-T (expertise · experience · authority · trust) across the entire therapeutic surface.
21 cfr part 11 electronic records biotechhipaa compliance patient education contentsoc 2 vendor due diligence pharma crofda title 21 part 202 advertising compliancebiotech vendor matcher soc 2 hipaa 21 cfr part 11Buy-side analysts, sell-side equity research, ESG screeners, and biotech-vertical investor search. These pages affect coverage initiation and target price models · measurable enterprise-value impact.
neurocrine post-acquisition pipeline 2026neurocrine biosciences pipeline timeline phase 3vmat2 franchise outlook 2026 2027 2028neurocrine endocrinology pipeline overviewbiotech acquisition synergy realization timelineOperator-honest comparison. Biotech digital agencies charge for retainer relationships and slide decks. SideGuy ships substrate.
| Line item | Biotech digital agency | SideGuy |
|---|---|---|
| Post-acquisition SEO audit | $15K · $40K (6-8 weeks) | $250 (3-5 days) |
| 10 longtail substrate pages | $25K · $60K (8-12 weeks) | $2,000 (10 days) |
| Python toolchain delivery | Not offered (SaaS lock-in) | Included · you own it |
| Ongoing daily maintenance | $8K · $15K/mo retainer | $500/mo · cancel anytime |
| QBR slide decks | Quarterly mandatory | Never |
| Annual savings · first year | Baseline | $80K · $200K saved |
Numbers assume agency mid-market quotes from publicly available biotech RFP outcomes. Actual agency quotes vary; SideGuy pricing is fixed.
Three structural reasons · not marketing puffery.
SOC 2 · HIPAA · 21 CFR Part 11 · FDA Title 21 · GxP electronic-records substrate already shipped 15+ pages deep. No ramp on Neurocrine's regulatory language. See the compliance hub →
The vendor-matcher quizzes shipped for SOC 2 · cyber-insurance · GRC platforms · cloud security map directly to biotech CRO/CMO selection, EDC platforms (Veeva · Medidata · OpenClinica), and 21 CFR Part 11 electronic-records vendors. Same generator pattern. Different vocabulary. Example matcher →
After the 10-day onboarding, Neurocrine owns: morning_lap.py (daily GSC audit) · generate_indication_pages.py (new therapeutic-area substrate) · noindex_thin_pages.py (post-acquisition cleanup) · sitemap automation. Stop the engagement at any point · Neurocrine keeps every tool. Same chassis runs on a 200K+ page operator substrate today.
Operator-honest delivery timeline. Async-by-default · daily ship updates in shared text thread · no Calendly · no QBR slide decks.
GSC + Bing Webmaster setup verification · post-acquisition canonical analysis · 301-redirect plan from acquired-domain · competitive positioning vs. Sage, Axsome, Intra-Cellular, Acadia · cluster prioritization · honest yes/no on continuing.
5-10 longtail pages live (Cluster 01 · 02 · 04) · operator-honest content within FDA label boundaries · proper schema (Article + FAQPage + MedicalCondition + Person) · internal link mesh built in.
Python toolchain handed over (morning_lap + 4 generators) · documentation · daily lap walkthrough · 30-day GSC monitoring plan · optional $500/mo ship-and-shave retainer if you want SideGuy to keep running it.
Three tiers. Pick the one that matches where Neurocrine actually is in the post-acquisition window. Most clients start at $250 to validate fit before $2K commitment.
GSC signal-quality audit · post-acquisition canonical analysis · competitor positioning · cluster map · operator-honest yes/no on continuing. Credited toward $2K onboarding if upgraded within 30 days.
Audit + cleanup + 5-10 substrate pages live + Python toolchain handed off. You own everything we built. Cancel anytime · no retainer.
Daily morning_lap.py run on Neurocrine's domain · 2-4 Tier-2 pages shipped weekly · GSC alerts handled. Only makes sense after Tier 2 onboarding · optional always.
Biotech digital agencies sell retainers · QBR slide decks · 12-month minimums · compliance-review theater · per-seat SaaS subscriptions · billable-hours invoicing. The KPI is hours invoiced. Monthly Medical/Legal/Regulatory review meetings nobody reads.
This approach ships actual pages · fixes actual canonical splits · deploys actual schema · hands off actual tools. The KPI is GSC signal lift. Zero retainer · zero Calendly · zero minimum. You own the substrate when it's done.
Plus: zero vendor commissions on tools recommended. If a recommendation says use Veeva or Medidata, it is because Veeva or Medidata is right · not because anyone is paying for placement.
DON'T EVENT PLAY →Everything proposed for Neurocrine · already proven at scale. The receipts ARE the pitch.
Related operator guide:
⚖️ 6 New California AI Laws · Operator GuideThe strategy is on this page. The $250 deposit formalizes it into a written deliverable + GSC signal-quality audit + execution-ready scope. 3-5 days from confirmation to audit delivery. Credited toward the $2K onboarding if you continue. No retainer · no Calendly · no email gate.
No back-and-forth · payment link arrives within 30 minutes · audit work begins on receipt.
Don't see what you were looking for?
Text PJ a sentence about what you actually need · I'll build you a free custom shareable on the house. No email, no funnel, no SOW.
📲 Text PJ · free shareable